Douglas A. Stewart, MD, FRCPC - Internal Medicine, Medical OncologyDr. Douglas Stewart reviews medical content for Healthwise, a
nonprofit organization with a mission to help people make better health
decisions. Dr. Stewart is a professor in the departments of Medicine and
Oncology, Divisions of Medical Oncology, Hematology, and Hematological
Malignancies, at the University of Calgary in Alberta. He is also a medical
oncologist in the Department of Medicine at the Tom Baker Cancer Centre and The
Calgary Health Region. Board Certifications- Specialist Certificate in Medical
Oncology
- FRCPC Internal Medicine
Healthwise Knowledgebase Topics Reviewed- Non-Hodgkin's Lymphoma
- Breast
Cancer
- Breast Cancer, Metastatic or
Recurrent
- Lymphedema
- Inflammatory Breast Cancer
Education- MD: With Distinction, University of Alberta,
Edmonton, AB, 1987
- FRCPC: Internal Medicine, Medical Oncology
Certification, University of Ottawa, Ottawa, ON, 1993
- Fellowship:
Bone Marrow Transplantation and Lymphoma, University of Nebraska, Omaha, NE,
1994
Academic Appointments- Professor, Departments of Oncology and
Medicine, University of Calgary
Hospital Affiliations- Tom Baker Cancer Centre
- The
Calgary Health Region
Professional Affiliations- Royal College of Physicians and Surgeons of
Canada
- Canadian Medical Protective Association
- Canadian
Association of Medical Oncologists
- Canadian Hematology
Society
- American Society of Clinical Oncology
- European
Bone Marrow Transplant Registry
- American Society of
Hematology
Selected Publications- Russell J, Savoie M L, Balogh A, Turner A R,
Larratt L, Chaudhry M A, Storek J, Bahlis N, Brown C, Quinlan D, Geddes M,
Stewart D (2007) Allogeneic transplantation for adult acute leukemia in first
and second remission with a novel regimen incorporating daily intravenous
busulfan, fludarabine, 400 CGY total body irradiation, and thymoglobulin.
Biology of Blood and Marrow Transplantation, 13(7):
814–821.
- Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L,
Morris DG, Jones A, Brown C, Russell JA (2006). Upfront double high dose
chemotherapy with DICEP followed by BEAM and autologous stem cell
transplantation for poor prognosis aggressive non-Hodgkin’s lymphoma.
Blood, 107(12): 4623–4627.
- Stewart DA,
Paterson AHG, Ruether JD, Russell J, Craighead P, Smylie M, Mackey J (2005).
High dose mitoxantrone-vinblastine-Cyclophosphamide and autologous stem cell
transplantation for stage III breast cancer: Final results of a prospective,
multicentre study. Annals of Oncology, 16(9): 1463–1468.
- Conner-Spady BL, Cumming C, Nabholtz J-M, Jacobs P, Stewart D
(2005). A longitudinal prospective study of health-related quality of life in
breast cancer patients following high-dose chemotherapy with autologous blood
stem cell transplantation. Bone Marrow Transplantation,
36(3): 251–259.
- Thirukkumaran CM, Luider JM, Stewart, DA, Cheng T,
Lupichuk SM, Nodwell MJ, Russell JA, Auer IA, Morris DM (2003). Reovirus
oncolysis as a novel purging strategy for autologous stem cell transplantation.
Blood, 102(1): 377–387.
Financial DisclosureDr. Stewart has received grants from the Alberta Cancer Foundation,
Hoffmann-La Roche, National Cancer Institute of Canada, Health Canada Best
Practices Contribution Program, Calgary Laboratory Services, and
GlaxoSmithKline.
| © 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
| 
| |
| |